Covalent Labs

Covalent Bioscience is a biotechnology company developing a novel class of therapeutics known as Catabodies (catalytic antibodies). Unlike traditional antibodies that bind to targets and rely on the immune system for clearance, Catabodies act as enzymes that irreversibly cleave and inactivate diseased proteins. The company's platform is designed to target and eliminate toxic proteins associated with aging and infectious diseases, including amyloid-beta and tau in Alzheimer's disease, and the gp120 protein in HIV. Covalent Bioscience aims to provide superior efficacy and safety compared to conventional monoclonal antibodies by utilizing a catalytic mechanism that allows a single Catabody molecule to neutralize thousands of target molecules.